Crossmark

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG)

Crossref DOI link: https://doi.org/10.1186/s12885-020-07011-z

Published Online: 2020-06-08

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Grosu, Anca-Ligia

Frings, Lars

Bentsalo, Iryna

Oehlke, Oliver

Brenner, Franziska

Bilger, Angelika

Fennell, Jamina Tara

Rothe, Thomas

Schneider-Fuchs, Sabine

Graf, Erika

Schmoor, Claudia

Beck, Jürgen

Becker, Gerhild

Bock, Michael

Egger, Karl

Urbach, Horst

Lahmann, Claas

Popp, Ilinca http://orcid.org/0000-0001-6702-3619
Funding

Funding for this research was provided by:

Deutsche Krebshilfe (110912)
License Information

Text and Data Mining valid from 2020-06-08

Version of Record valid from 2020-06-08
More Information

Article History

Received: 15 April 2020

Accepted: 27 May 2020

First Online: 8 June 2020

Ethics approval and consent to participate

: The HIPPORAD trial has been approved by the Ethics Committee, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany (No. 108/16, date of approval for version 1.0. 03.05.2016, version 3.0. 20.12.2018). Written informed consent is obtained from all participants of the trial.

: Not applicable.

: Prof. Jürgen Beck has been invited to be an associate editor for BMC. The authors declare no other competing interests.

Document is current

Any future updates will be listed below